ctrl K

Watchlist Price Alert

Anebulo Pharmaceuticals I... (ANEB)

NASDAQ: ANEB · Real-Time Price · USD

1.40

-0.07 (-4.76%)

At close: Jun 27, 2025, 11:15 AM

Anebulo Pharmaceuticals Income Statement

Financials in USD. Fiscal year is July - June.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	n/a	n/a	n/a	n/a	n/a
Gross Profit	n/a	n/a	n/a	n/a	n/a
Operating Income	-8.31M	-11.78M	-6.83M	-3.61M	-173.35K
Interest Income	249.02K	92.41K	7.33K	1.02K	n/a
Pretax Income	-8.2M	-11.73M	-6.83M	-30.25M	-174.64K
Net Income	-8.2M	-11.73M	-6.83M	-30.25M	-174.64K
Selling & General & Admin	4.76M	6.18M	3.87M	1.34M	23.35K
Research & Development	3.55M	5.6M	2.96M	2.27M	150K
Other Expenses	n/a	-41.15K	-1.78K	-1.34K	n/a
Operating Expenses	8.31M	11.78M	6.83M	3.61M	173.35K
Interest Expense	151.23K	n/a	7.33K	11.77K	1.29K
Selling & Marketing Expenses	4.8K	n/a	n/a	n/a	23.21K
Cost & Expenses	8.31M	11.78M	6.83M	3.61M	173.35K
Income Tax Expense	n/a	-104K	-12.89K	10.75K	-1.04K
Shares Outstanding (Basic)	25.82M	25.07M	23.34M	13.61M	23.72M
Shares Outstanding (Diluted)	25.82M	25.07M	23.34M	13.61M	23.72M
EPS (Basic)	-0.32	-0.47	-0.29	-2.83	-0.01
EPS (Diluted)	-0.32	-0.47	-0.29	-2.83	-0.01
EBITDA	-8.05M	-11.78M	5.55K	-30.24M	-173.35K
EBIT	-8.05M	-11.73M	-6.83M	-30.24M	-1.04M
Depreciation & Amortization	258.28K	11.78M	6.83M	n/a	1.04M